Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 43Genitourinary 43Other solid neoplasm 13Gastrointestinal 12Gynecologic 11Thoracic 10Head & Neck 9Breast 9Tumor-Agnostic 6Dermatologic 4CNS 4Endocrine 3NET 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × pazopanib × NET × Clear all
NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
44 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT01099540 2015-12-29

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Phase 2 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡